Evidence to experience-Topical PDE4 inhibitor in Atopic Dermatitis

Speciality: Dermatology

Description:

A warm welcome to all the medical professionals in this interesting session on Evidence to experience-Topical PDE4 inhibitor in Atopic Dermatitis
Topical phosphodiesterase 4 (PDE4) inhibitors have become an innovative option in managing atopic dermatitis (AD), particularly for patients with mild to moderate forms of the disease. Clinical trials have shown that PDE4 inhibitors, such as crisaborole, effectively reduce inflammation and pruritus by inhibiting the PDE4 enzyme, which plays a crucial role in the inflammatory cascade associated with AD. These studies report significant improvements in skin clearance and symptom relief compared to placebo, with a favorable safety profile.
The transition from clinical evidence to real-world experience has reinforced the utility of topical PDE4 inhibitors in daily practice. Patients and dermatologists have noted the benefits of non-steroidal options, particularly for long-term use and on sensitive skin areas where corticosteroids may pose risks. Adverse effects are generally mild, with application site pain being the most commonly reported issue, which is typically transient.
Therefore, get an overall knowledge of evidence to experience-topical PDE4 inhibitor in atopic dermatitis
 

See More Webinars @ Hidoc Webinars